IRIS Institutional Research Information System - OPENBS Open Archive UniBS

FOCA', Emanuele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.221
AS - Asia 4.636
EU - Europa 4.077
SA - Sud America 1.003
AF - Africa 142
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 14
AN - Antartide 1
Totale 18.111
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.055
SG - Singapore 1.666
CN - Cina 1.353
IT - Italia 918
BR - Brasile 857
UA - Ucraina 684
DE - Germania 673
HK - Hong Kong 643
PL - Polonia 385
VN - Vietnam 355
GB - Regno Unito 309
FI - Finlandia 297
RU - Federazione Russa 235
TR - Turchia 196
IE - Irlanda 150
FR - Francia 98
IN - India 96
CA - Canada 77
NL - Olanda 73
BD - Bangladesh 66
SE - Svezia 64
MX - Messico 59
AR - Argentina 57
JP - Giappone 47
BF - Burkina Faso 41
AT - Austria 40
ZA - Sudafrica 40
ES - Italia 34
ID - Indonesia 34
CZ - Repubblica Ceca 30
IQ - Iraq 28
EC - Ecuador 21
SA - Arabia Saudita 19
BE - Belgio 18
LT - Lituania 17
PK - Pakistan 16
AU - Australia 15
EU - Europa 14
UZ - Uzbekistan 14
AE - Emirati Arabi Uniti 13
JO - Giordania 13
CL - Cile 12
IL - Israele 12
PE - Perù 12
VE - Venezuela 12
CO - Colombia 11
KE - Kenya 11
EG - Egitto 9
AZ - Azerbaigian 8
JM - Giamaica 8
MA - Marocco 8
PY - Paraguay 8
CH - Svizzera 7
PT - Portogallo 7
TN - Tunisia 7
CR - Costa Rica 6
KZ - Kazakistan 6
LK - Sri Lanka 6
UY - Uruguay 6
BO - Bolivia 5
CI - Costa d'Avorio 5
IR - Iran 5
BG - Bulgaria 4
BY - Bielorussia 4
KR - Corea 4
MK - Macedonia 4
MY - Malesia 4
SK - Slovacchia (Repubblica Slovacca) 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
UG - Uganda 4
AM - Armenia 3
CG - Congo 3
GE - Georgia 3
GR - Grecia 3
HN - Honduras 3
LV - Lettonia 3
MU - Mauritius 3
NP - Nepal 3
PA - Panama 3
PH - Filippine 3
RO - Romania 3
SY - Repubblica araba siriana 3
AL - Albania 2
BH - Bahrain 2
CM - Camerun 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
EE - Estonia 2
GY - Guiana 2
HU - Ungheria 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
NG - Nigeria 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
OM - Oman 2
SN - Senegal 2
AQ - Antartide 1
BB - Barbados 1
Totale 18.095
Salva come PNG Salva come JPEG
Città #
Fairfield 842
Singapore 788
Ashburn 729
Hong Kong 640
Woodbridge 618
Jacksonville 522
Houston 415
Chandler 396
Warsaw 378
Seattle 359
Wilmington 342
Beijing 336
Ann Arbor 319
Cambridge 299
New York 288
Princeton 269
Los Angeles 198
Helsinki 186
Nanjing 165
Munich 159
Brescia 158
Istanbul 158
Dublin 147
Ho Chi Minh City 129
The Dalles 117
Dallas 116
Des Moines 78
Milan 77
Moscow 76
Shanghai 73
Buffalo 72
Redondo Beach 65
São Paulo 64
Dearborn 62
Chicago 59
San Francisco 59
Hanoi 57
Nanchang 53
Tianjin 52
San Diego 49
Turku 47
Changsha 46
Jinan 45
Shenyang 45
London 43
Tokyo 43
Ouagadougou 40
Hebei 37
Nuremberg 36
Santa Clara 36
Lancaster 34
Boardman 30
Frankfurt am Main 30
Orem 28
Belo Horizonte 27
Toronto 27
Brooklyn 26
Rome 26
Jiaxing 25
Montreal 25
Poplar 25
Rio de Janeiro 25
Zhengzhou 25
Hangzhou 24
Brno 23
Düsseldorf 23
Haiphong 23
Stockholm 23
Chennai 22
Denver 22
Phoenix 22
Vienna 21
Amsterdam 20
Johannesburg 20
Mexico City 20
Ningbo 20
Boston 19
Romola 19
Bologna 18
Kunming 18
Taizhou 18
Washington 18
Brussels 17
Verona 17
Atlanta 16
Curitiba 16
Dong Ket 16
Salt Lake City 16
Brasília 15
Dhaka 15
Manchester 15
Mumbai 15
Charlotte 14
Jakarta 14
Kyiv 14
Lappeenranta 14
Biên Hòa 13
Newark 13
Porto Alegre 13
Amman 12
Totale 11.398
Salva come PNG Salva come JPEG
Nome #
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 396
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study 252
Calculated Decisions: Brescia-COVID Respiratory Severity Scale (BCRSS)/Algorithm 235
A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz 220
The Disagreement Among Methods to Evaluate Glomerular Filtration Rate in HIV-Infected Patients Naive to Antiretroviral Therapy. 220
Effectiveness of routine lumbar puncture in patients with HIV-associated Dementia (HAD) receiving suppressive antiretroviral treatment 215
Cohort profile: Standardized management of antiretroviral therapy cohort (MASTER cohort) 206
Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study. 202
Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy 195
Evaluation of Liver Fibrosis: Concordance Analysis between Noninvasive Scores (APRI and FIB-4) Evolution and Predictors in a Cohort of HIV-Infected Patients without Hepatitis C and B Infection 193
Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study 191
Prevalence of integrase strand transfer inhibitors (InSTIs) resistance mutations in InSTIs-naive and -experienced HIV-1 infected patients: a single Center experience 185
Clinical and Immunological outcomes according to adherence to first-line HAART in a urban and rural cohort of HIV-infected patients in Burkina Faso, West Africa 183
Cryptogenic liver diseases: sailing by sight from HIV co-infection with hepatitis viruses to HIV mono-infection through the Pillars of Hercules. 179
Screening for Neurocognitive Impairment in HIV-Infected Individuals at First Contact after HIV Diagnosis: The Experience of a Large Clinical Center in Northern Italy 179
Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: A substudy of the NEAT001/ANRS143 randomised trial 178
Prospective evaluation of bone markers, parathormone and 1,25-(OH)2 vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz. 170
Neutrophil to Lymphocyte Ratio and Cardiovascular Disease Incidence in HIV-Infected Patients: A Population-Based Cohort Study 165
Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: A Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians 164
Incidence of cardiovascular events in HIV-positive patients compared to general population over the last decade: a population-based study from 2000 to 2012 161
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: Raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART 161
Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: Routine evidence from the Italian MASTER Cohort 159
Virological effectiveness and CD4+ T-cell increase over early andlate courses in HIV infected patients on antiretroviral therapy: focus on HCV andanchor class received 154
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy 151
Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus 148
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: A MASTER cohort study 147
Long-lasting humoral immune response induced in HIV-1-infected patients by a synthetic peptide (AT20) derived from the HIV-1 matrix protein p17 functional epitope. 146
Asymptomatic neurocognitive disorders in patients infected by HIV: fact or fiction? 145
Comparison between the gold standard DXA with calcaneal quantitative ultrasound based-strategy (QUS) to detect osteoporosis in an HIV infected cohort 145
Prevalence of non-B HIV-1 subtypes in North Italy and analysis of transmission clusters based on sequence data analysis 145
Phenotypic and genotypic evaluation of slime production by conventional and molecular microbiological techniques 144
Effectiveness of kidney transplantation in HIV-infected recipients under combination antiretroviral therapy: a single-cohort experience (Brescia, Northern Italy) 144
Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients 144
Disseminated Histoplasmosis as AIDS-presentation. Case Report and Comprehensive Review of Current Literature 144
For timing of HAART is less more? CD4+/CD8+ ratio and CD4+ percentage as surrogate markers for more complex immunological features. 143
Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy 143
Impact of detectable human cytomegalovirus DNAemia on viro-immunologicaleffectiveness of HAART in HIV-infected patients naive to antiretroviral therapy 141
UVA1 phototherapy as a treatment option for plaque psoriasis in HIV-positive patients 141
Survival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an italian multicenter study. 138
DTG prescribing patterns in PLWH ≥65 years: the impact of 2DR and weight gain 138
Coinfezione HIV/HBV in Burkina Faso, Africa Occidentalele 137
High prevalence of radiological vertebral fractures in HIV-infected males 135
Increase in Standard Cholesterol and Large HDL Particle Subclasses in Antiretroviral-Naïve Patients Prescribed Efavirenz Compared to Atazanavir/Ritonavir 135
Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort 135
Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study 134
Adverse events associated to HAART in Burkina Faso 131
Malaria and HIV in adults: When the parasite runs into the virus 129
Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: An Italian randomized clinical trial 127
Malaria prophylaxis. A comprehensive review 126
Pharmacokinetic Changes during Pregnancy According to Genetic Variants: A Prospective Study in HIV-infected Patients Receiving Atazanavir/Ritonavir 126
Serological Response to SARS-CoV-2 in Health Care Workers Employed in a Large Tertiary Hospital in Lombardy, Northern Italy 125
Coming home to be cared. Emigration and antiretroviral treatment in the Nanoro health district, Burkina Faso. 125
Elderly women with human immunodeficiency virus infection: is there an effect of the virus on neuropsychological prolife? 125
Perinatally HIV-Infected Youths After Transition from Pediatric to Adult Care, a Single-Center Experience from Northern Italy 125
Clinical presentation and outcomes of SARS-CoV-2 related encephalitis: the ENCOVID multicentre study 124
Management of neurocysticercosis in Northern Italy: presentation of 11 cases and review of the literature on an emerging infection 123
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 123
HIV/HBV and HIV/HCV co-infection in Burkina Faso, West Africa 122
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 122
The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 - 74 years and more than 75 years 121
Prognostic role of inflammatory biomarkers in HIV-infected patients with a first diagnosis of Hepatocellular carcinoma (HCC): a single-centre study 120
Qualitative and quantitative analysis of mortality and morbidity at the health facilities in the rural district of Nanoro, Burkina Faso 118
Drug-specific risk of adverse events onset related to HAART in a resource-limited setting from 2001 to 2009: the experience of 3 medical centers in Burkina Faso 118
The use of ultrasonography, transient elestography, APRI and FIB-4 to measure liver steatosis and fibrosis in HIV-positive patients not co-infected with hepatitis viruses with hypertransaminasemia of unknown origin on HAART 117
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 117
The good, the bad and the ugly: Determinants of antiretroviral-associated toxicities 115
Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV 114
Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection. 113
Amebiasi e infezione da amebe a vita libera 113
Disengagement and reengagement of HIV continuum of care in a single center cohort in northern Italy 112
International migrations and HIV care in the rural District of Nanoro, Burkina Faso 112
The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: Results of a 3-year cohort study 111
Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, Italy 111
Role of Normalized T-Cell Subsets in Predicting Comorbidities in a Large Cohort of Geriatric HIV-Infected Patients 110
Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities: is it time to assess the definitions? 110
Coming home to be cared. Emigration and antiretroviral treatment in the Nanoro health District, Burkina Faso 109
Infezioni intestinali da protozoi e tricomoniasi 106
Laboratory considerations amidst the coronavirus disease 2019 outbreak: the Spedali Civili in Brescia experience 106
Impact of genotypic susceptibility score on cART outcomes during primary HIV infection 104
Pregnancy related immune-deficit in HIV-infected pregnant women in resource-limited countries. Implications for HAART initiation 100
Sexuality, pregnancy and procreation desire among HIV+ patients in Ouagadougou, Burkina Faso 100
Presence of V72I, G123S and R127K Integrase Inhibitor polymorphisms could reduce ART effectiveness: a retrospective longitudinal study 99
Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover 99
Steroid-Responsive Encephalitis in Coronavirus Disease 2019 99
SARS-CoV-2 invades the West. How to face a COVID-19 epidemic in Lombardy, Northern Italy? 99
SARS-CoV-2 encephalitis is a cytokine release syndrome: evidences from cerebrospinal fluid analyses 99
Co-infection of chlamydia pneumoniae and mycoplasma pneumoniae with SARS-CoV-2 is associated with more severe features 98
User fees and compliance to HAART in Ouagadougou, Burkina Faso 98
Confronto della efficacia della TARV tra popolazione urbana e rurale in un contesto a risorse limitate 97
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry 97
Unboosted Atazanavir for Treatment ofHIV Infection: Rationale and Recommendations for Use 96
Correction to: Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression (The Patient - Patient-Centered Outcomes Research, (2020), 13, 3, (375-387), 10.1007/s40271-020-00413-y) 96
Monitoring the toxicity related to HAART from 2001 to 2009 in Burkina Faso: clinical adverse events vs. laboratori adverse events: prevalence, grading and outcome 95
Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian “GEPPO” Cohort 95
Immunological Evolution of a Cohort of HIV-2 Infected Patients: Peculiarities of an Underestimated Infection 93
A 2021 update on syphilis: Taking stock from pathogenesis to vaccines 93
Low-dose Lung Radiotherapy for COVID-19-related Pneumonia: Preliminary Results of the Italian Mono-institutional COLOR-19 Trial 92
Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART 91
HIV-1 mutants expressing B cell clonogenic matrix protein p17 variants are increasing their prevalence worldwide 90
An HIV elite controller patient carrying the homozygous H63D variant in the homeostatic iron regulator gene: A case report 90
Totale 13.712
Salva come PNG Salva come JPEG
Categoria #
all - tutte 93.081
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 93.081
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.319 0 0 0 0 0 231 117 228 207 272 185 79
2021/20221.208 85 156 25 77 42 71 74 89 67 134 103 285
2022/20231.187 157 19 23 82 112 293 5 124 218 10 77 67
2023/20241.449 91 27 124 107 67 272 64 62 317 25 54 239
2024/20253.566 41 36 41 447 322 330 292 157 426 346 677 451
2025/20264.460 697 856 512 1.133 937 325 0 0 0 0 0 0
Totale 18.543